Liscastobart

立卡苏拜单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameLiscastobart
Drug Alias NameRecombinant humanized anti PD-1 monoclonal antibody(Bio-Thera Solutions)BAT-1308
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsEndometrial Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBio-Thera Solutions Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsEndometrial Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A